Fig. 2

Intravitreal injection of α-synuclein fibrils leads to pS129 accumulation in the retina. A pS129-positive inclusions in the INL and IPL at 2 and 5 months after injection. Arrows indicate cell body inclusions in the INL. Close up shows neurite-like inclusions in the IPL. Scale bar: 50 µm. B Quantification of the relative immunoreactivity intensity of pS129 staining in the IPL at 2 months and 5 months post injection. C Quantification of pS129-positive cell inclusions in the border of the INL at 2 months and 5 months post injection. D Representative images of colocalization of α-synuclein and pS129 in the INL. E Colocalization of pS129 and amacrine cell marker AP2. Scale bar: 20 µm. F–G Representative western blot images of α-synuclein in the soluble and insoluble fractions obtained from the whole retinal lysates at 2 months (F) and 5 months (G) after injection. Arrowheads show quantified monomer and truncated α-synuclein. H–K Quantification of monomer, aggregated (above 20 kDa) and truncated α-synuclein in the soluble (H, J) and insoluble fractions (I, K) at 2 months (H, I) and 5 months (J, K) after injection. Data in B-C and H–K are expressed as means ± s.e.m. (PBS, n = 5 mice; PFF, n = 5 mice; *p < 0.05, **p < 0.01, ***p < 0.001; Student’s t-test and Two-way ANOVA)